News Archivi - Vetos Europe - Anavrin

Announcement: New Trial on the Effects of Anavrin on Methane Reduction in Ruminants

We are excited to announce that Anavrin has commenced a new trial in collaboration with the Università degli Studi di Milano . This trial focuses on calves and aims to confirm the effectiveness of our product for use in young ruminants, specifically measuring its...

EU Decision on Antimicrobial Compounds: A Shift Towards Natural Alternatives

News

The European Union (EU) has officially approved a significant regulatory decision to ban the import of edible animal products derived from animals treated with antimicrobial compounds, including Monensin, for growth promotion after September 2026. This regulatory...

Exciting Announcement!

News

We are thrilled to share that our abstract titled “Evaluating the effects of a methane mitigating additive (Anavrin) on feed intake, milk production, and emissions in Holstein dairy cows,” developed at Wageningen University & Research, has been...

Exciting News in Dairy Production

News

I am thrilled to announce that our trial conducted on dairy cows at the Aira cooperative in collaboration with the University of Barcelona has been approved for presentation at the upcoming EAAP – European Federation of Animal Science Congress 2025 in Innsbruck!...

Exciting Results from our Unprecedented 7 Months Trial with GreenFeed on Beef Cattle!

News

We are thrilled to announce the remarkable outcomes of a one-of-a-kind trial in Europe, conducted over an extensive 210 days (7months) in collaboration with Università degli Studi di Milano. This extensive period allowed us to gain unparalleled insights into measuring...

Exciting Milestone Update on Anavrin’s Long-term Trial utilizing GreenFeed for Methane Emissions Measurement!

News

We are thrilled to share that it has been 210 days (7months) since we initiated our long-term trial focusing on methane emission reduction and performance enhancement in beef cattle at the prestigious Università degli Studi di Milano ! This extensive trial represents...